Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 114Lung Neoplasms 83Lymphoma 76Head and Neck Neoplasms 76Glioblastoma 75Squamous Cell Carcinoma of Head and Neck 71Breast Neoplasms 71Rectal Neoplasms 67Esophageal Neoplasms 63Prostatic Neoplasms 59Leukemia 57Central Nervous System Neoplasms 54Pancreatic Neoplasms 51Precursor Cell Lymphoblastic Leukemia-Lymphoma 47Lymphoma, Non-Hodgkin 43Lymphoma, Large B-Cell, Diffuse 43Hodgkin Disease 42Lymphoma, Follicular 41Brain Neoplasms 40Leukemia, Lymphocytic, Chronic, B-Cell 39Esophageal Squamous Cell Carcinoma 39Colorectal Neoplasms 38Burkitt Lymphoma 37Gliosarcoma 36Lymphoma, Large-Cell, Immunoblastic 33Uterine Cervical Neoplasms 31Neoplasms 31Adenocarcinoma Of Esophagus 31Lymphoma, Mantle-Cell 30Lymphoma, B-Cell, Marginal Zone 29

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HER2 Positive Esophagogastric Cancer × Radiotherapy × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡